|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:can_be_combined_with
|
gptkb:lenalidomide
|
|
gptkbp:class
|
biologic therapy
|
|
gptkbp:clinical_trial
|
Phase 2
published in journals
L-MIND trial
|
|
gptkbp:clinical_use
|
oncology
|
|
gptkbp:contraindication
|
hypersensitivity to tafasitamab
|
|
gptkbp:developed_by
|
Morpho Sys AG
|
|
gptkbp:dosage_form
|
solution for infusion
based on body weight
|
|
gptkbp:drug_interactions
|
limited data available
|
|
gptkbp:duration
|
up to 12 cycles
|
|
gptkbp:effective_date
|
gptkb:2020
|
|
gptkbp:eligibility
|
specific criteria
|
|
gptkbp:fdaapproval_type
|
BLA
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:healthcare
|
yes
trained in administration
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tafasitamab
|
|
gptkbp:indication
|
B-cell malignancies
|
|
gptkbp:interacts_with
|
live vaccines
|
|
gptkbp:is_monitored_by
|
required during treatment
blood counts
|
|
gptkbp:knockouts
|
high affinity for CD19
|
|
gptkbp:lifespan
|
approximately 12 days
|
|
gptkbp:marketed_as
|
gptkb:Monjuvi
|
|
gptkbp:mechanism_of_action
|
targets CD19
|
|
gptkbp:partnership
|
gptkb:Incyte_Corporation
|
|
gptkbp:patient_education
|
important for safety
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmaceutical_formulation
|
sterile solution
|
|
gptkbp:pharmacokinetics
|
antibody-dependent cellular cytotoxicity
linear pharmacokinetics
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
outpatient
NCCN guidelines
|
|
gptkbp:research
|
ongoing studies
|
|
gptkbp:research_focus
|
gptkb:B-cell_lymphomas
|
|
gptkbp:rounds
|
metabolism
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:second_line_treatment
|
indicated
|
|
gptkbp:service_frequency
|
once weekly
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
infections
infusion-related reactions
cytopenia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:structure
|
gptkb:Ig_G1
|
|
gptkbp:supply_chain
|
managed by manufacturer
|
|
gptkbp:targets
|
B cells
|
|
gptkbp:treatment
|
combination therapy
under investigation
varies by patient
remission
improved survival rates
not indicated
|
|
gptkbp:used_for
|
treatment of relapsed or refractory diffuse large B-cell lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Mitsubishi_Tanabe_Pharma
|
|
gptkbp:bfsLayer
|
5
|